Navigation Links
New Analyses Confirm Nexavar's Efficacy and Safety in Multiple Patient Subsets With Liver Cancer
Date:10/31/2008

- Subanalyses from the Phase 3 SHARP and Asia-Pacific trials to be presented at 59th Annual Meeting of the American Association for the Study

of Liver Diseases -

WAYNE, N.J. and EMERYVILLE, Calif., Oct. 31 /PRNewswire-FirstCall/ -- Bayer HealthCare Pharmaceuticals, Inc. and Onyx Pharmaceuticals, Inc. (Nasdaq: ONXX) today announced that new Nexavar data will be presented at the upcoming 59th Annual Meeting of the American Association for the Study of Live Diseases (AASLD) demonstrating the clinical application of Nexavar(R) (sorafenib) tablets in multiple patient subsets with hepatocellular carcinoma (HCC), or liver cancer. Nexavar is the only systemic treatment to demonstrate prolonged overall survival in unresectable HCC and is currently approved in more than 60 countries for the treatment of the disease.

Data will be presented evaluating specific patient subpopulations from the Phase 3 SHARP (Sorafenib HCC Assessment Randomized Protocol) and Asia Pacific trials. The trials enrolled 602 and 226 patients, respectively, with advanced, unresectable HCC who had not received prior systemic therapy. Patients in both studies were randomized to receive either Nexavar 400 mg twice daily or placebo. Data from both Phase 3 trials demonstrated that patients treated with Nexavar experienced a significant improvement in overall survival; 44% (HR=0.69; p-value=0.0006) in the SHARP trial and 47% (HR=0.68; p-value=0.014) in the Asia Pacific trial.

"The SHARP and Asia Pacific trials continue to increase our understanding and provide clinical confirmation of the efficacy, safety and clinical benefit of Nexavar in patients with liver cancer," said Mark Gelder, MD, vice president, Therapeutic Area Oncology
'/>"/>

SOURCE Bayer HealthCare Pharmaceuticals, Inc.; OnyxPharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine news :

1. New Analyses of long-term LIALDA (mesalamine) data presented at ACG
2. Data from Pooled Analyses Demonstrates Welchol, Combined with Metformin- or Sulfonylurea-Based Therapy, Significantly Lowers Blood Glucose in Adults with Type 2 Diabetes
3. GAO Report Confirms: Medicare Underpays for Anesthesia Services; Nurse Anesthetists Assure Seniors Access to Safe Anesthesia Care
4. University of Texas Study Details Lengthy Payment Delays for Medicare Part D Prescription Drug Claims, Confirming Need for Legislative Fix
5. University of Nevada School of Medicine Professor Confirms Accuracy Through Validation Study Using the CSI Health Station Model 6K
6. PA Game Commission: EHD Outbreak Update: Test Results Confirm EHD In Beaver County
7. Actavis Confirms its Patent Challenge of Kings Avinza(R)
8. Barr Confirms Patent Challenge of UROXATRAL(R)
9. Pennsylvania Game Commission Announces EHD Confirmed in Allegheny and Westmoreland Counties
10. Perrigo Confirms Filing for Generic Version of Mucinex(R) and Announcement of Lawsuit by Adams Respiratory
11. Use of Technology to Document Comorbid Conditions May Improve Reimbursement, Increase Documentation Accuracy Study Confirms
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/25/2015)... The impact of the Trivedi Master ... of the public and is likely to cause further, ... and June. From March 21st to March 31st, ... "Special Prayers." More than 600 people participated in the ... and have reported intense experiences that they attest have ...
(Date:4/25/2015)... April 25, 2015 The URO CENTER of ... has been chosen by the New York Academy of Medicine ... medicine in the field of Urology. , Dr. Ferdinand Valentine, ... speciality, Genito-Urinary diseases. He was a man of rare ... of urology. Not only did he devote his life ...
(Date:4/24/2015)... 2015 Bird B Gone, the leader in ... offers a complete line of bird control solutions to address ... New Flu Strains Threaten Pacific, Central and Mississippi Farms , ... , a number of highly pathogenic avian flus in the ... often spread when wild birds enter poultry farms. The USDA ...
(Date:4/24/2015)... Ryadon is a leading manufacturer of custom ... services to complement any custom hardware requirements you may ... be offered on all heavy duty drawer slides ( ... discount - Order 20+: Receive 20% discount , Industries ... Furniture ,Drawer Slides, Inc. ...
(Date:4/24/2015)... 2015 The 1975 have had ... across the globe to theaters, festivals and TV performances. Now ... partnered with their label, Dirty Hit Records, to provide clean ... the newly launched Cadence & Cause website, this ... on vinyl and a signed photo card. Entries from ...
Breaking Medicine News(10 mins):Health News:Trivedi Master Wellness™ Announces the Resounding Success of their Special Prayers Human Wellness Program 2Health News:Trivedi Master Wellness™ Announces the Resounding Success of their Special Prayers Human Wellness Program 3Health News:The 2015 Valentine Award Comes From The Heart and Goes To Famous New York Urologist 2Health News:The 2015 Valentine Award Comes From The Heart and Goes To Famous New York Urologist 3Health News:Bird B Gone Offers Solutions to Bird Flu Threat to Poultry Farms 2Health News:Bird B Gone Offers Solutions to Bird Flu Threat to Poultry Farms 3Health News:Bird B Gone Offers Solutions to Bird Flu Threat to Poultry Farms 4Health News:Ryadon Inc. Offers Quantity Drawer Slide Discount Program Nationwide in May 2015 2Health News:Ryadon Inc. Offers Quantity Drawer Slide Discount Program Nationwide in May 2015 3Health News:Internationally Recognized British Indie Rock Outfit The 1975 Partner with Cadence & Cause to Provide Clean Drinking Water to Those in Need 2
... 28 Nutrition 21, Inc.,(Nasdaq: NXXI ), ... consumers manage blood sugar levels, improve cardiovascular health,enhance ... two new,additions to its Iceland Health(R) brand portfolio: ... Plus SLEEP Support.,Formulated with omega-3 fish oil and ...
... Noor came to,the attention of the Battalion Commander of ... Brigade Combat Team through an,unfortunate shooting incident from a ... little girl,s uncle. The initial diagnosis made by Lt.,Col. ... blind,due to a birth defect that resulted in poorly ...
... 28 OrbusNeich today announced that it,has received approval ... R stent in Taiwan., The Genous stent is ... cells (EPCs) circulating in the bloodstream. When,attracted to the ... shown to,quickly form a healthy layer of endothelium that ...
... 28 Watson,Pharmaceuticals, Inc. (NYSE: WPI ), ... New Drug Application (NDA) for oxybutynin,chloride topical gel ... U.S. Food,and Drug Administration (FDA). Watson is seeking ... hydrochloride for the treatment of,overactive bladder (OAB)., ...
... account for nearly all of the increase in U.S. singleton ... national birth data. , Between 1996 and 2004 there ... 92 percent of those infants were delivered by a cesarean ... of Dimes and the U.S. Centers for Disease Control and ...
... 27 It is estimated that there were ... Did you know that,African-American women have a 50 ... A new campaign, One4One, is empowering women to,help ... increase cervical,cancer education programs for women in multicultural ...
Cached Medicine News:Health News:Nutrition 21 Launches Iceland Health(R) Cholesterol Health and Iceland Health(R) Joint Relief Plus SLEEP Support 2Health News:Nutrition 21 Launches Iceland Health(R) Cholesterol Health and Iceland Health(R) Joint Relief Plus SLEEP Support 3Health News:Nutrition 21 Launches Iceland Health(R) Cholesterol Health and Iceland Health(R) Joint Relief Plus SLEEP Support 4Health News:Photos: Los Angeles Non Profit Teams With US Troops Stationed in Baghdad and Buaytha in Bringing a 5-Year-Old Blind Iraqi Girl, Whose Father Stands Beside US Combat Team Against Al Qaeda, to the US for a Groundbreaking Artificial Corneal Transplant Surger 2Health News:OrbusNeich Receives Approval to Market Genous(TM) Bio-engineered R stent(TM) in Taiwan 2Health News:Watson Announces Oxybutynin Topical Gel NDA Accepted for Filing by FDA for the Treatment of Overactive Bladder 2Health News:Watson Announces Oxybutynin Topical Gel NDA Accepted for Filing by FDA for the Treatment of Overactive Bladder 3Health News:Watson Announces Oxybutynin Topical Gel NDA Accepted for Filing by FDA for the Treatment of Overactive Bladder 4Health News:Watson Announces Oxybutynin Topical Gel NDA Accepted for Filing by FDA for the Treatment of Overactive Bladder 5Health News:C-sections a critical factor in preterm birth increase 2
(Date:4/25/2015)... Spain , April 25, 2015  With the ... benefits of precision cranial radiosurgery are now available for ... and sizes. This latest generation stereotactic radiosurgery system for ... imaging technologies, significantly increasing the versatility of Gamma Knife ... the 3 rd ESTRO Forum in ...
(Date:4/24/2015)... -- Perrigo Company plc ("Perrigo" or the "Company") (NYSE: PRGO, ... from Mylan NV ("Mylan") (NASDAQ: MYL ) to ... $60.00 per share in cash and 2.2 Mylan ordinary ... The Board previously concluded that Mylan,s unsolicited ... and its future growth prospects and was not in ...
(Date:4/24/2015)...  IGI Laboratories, Inc. (NYSE MKT: IG), a ... company, announced the Company will hold a conference call ... to discuss the 1st quarter 2015 results. ... by dialing 1-888-346-3479. International participants should call 1-412-902-4260. Canadian ... joined into the IGI Laboratories, Inc. call. ...
Breaking Medicine Technology:New Leksell Gamma Knife to benefit more patients with brain disease 2New Leksell Gamma Knife to benefit more patients with brain disease 3Perrigo Rejects Mylan Unsolicited Offer 2Perrigo Rejects Mylan Unsolicited Offer 3Perrigo Rejects Mylan Unsolicited Offer 4
... England, July 29, 2011 , ... The UK bioindustry has raised over $250m in financing ... any quarter for one year, and the second largest amount raised ... to the financing drought that saw three consecutive quarters below $100m ...
... Health Company (Nasdaq: FHCO ) today announced that ... operating results for the third quarter and first nine months ... Eastern Time (EDT).  The Company expects to report its operating ... other interested parties may participate in the conference call by ...
Cached Medicine Technology:UK Chalks Up $253 Million in Investment in Q2 2011: Oxford Cluster Takes the Largest Bite of the Apple 2UK Chalks Up $253 Million in Investment in Q2 2011: Oxford Cluster Takes the Largest Bite of the Apple 3The Female Health Company to Host Third Quarter Conference Call on Friday, August 5, 2011 2
Inquire...
Benchtop UV Incubator is designed to provide precise temperature control and uniformity throughout the chamber. Decontaminate chamber between experiments with built-in shortwave UV....
Inquire...
Inquire...
Medicine Products: